Not available in the U.S.
Gemigliptin
ZEMIGLO
What it isOral DPP-4 inhibitor that raises incretin (GLP-1/GIP) levels to enhance glucose-dependent insulin secretion.
Why this oneA weight-neutral, low-hypoglycemia oral option for type 2 diabetes, approved in South Korea (Zemiglo) rather than the US.
What limits itLike other gliptins it carries a risk of pancreatitis and arthralgia, and being non-FDA-approved it has limited US prescribing and interaction data.
NO BOXED WARNINGS
Principal riskNo FDA boxed warning.
Classes and tags
Clinical profile
Mechanism of action: Gemigliptin ballicule
